PM emphasises the need to enhance lab surveillance & testing of all Severe Acute Respiratory Illness (SARI) cases & ramp up genome sequencing
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
Mock drills are being conducted across the country to review the preparedness for management of COVID-19
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Centre and states need to work in tandem and in a collaborative spirit as was done during the previous surges for COVID-19 prevention and management
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Subscribe To Our Newsletter & Stay Updated
